Allarity Therapeutics announced on October 22, 2024, that the European Patent Office (EPO) will grant a patent for its Drug Response Predictor (DRP) companion diagnostic specific to stenoparib, the company's dual-targeted PARP/Tankyrase inhibitor. This patent strengthens Allarity's market position for both stenoparib and its companion diagnostic technology, which identifies patients most likely to benefit from treatment.The company is pursuing patent applications for the Stenoparib DRP companion diagnostic in other major markets, including the United States, Japan, China, Australia, and India. Allarity has already secured 17 patents for drug-specific DRPs, with eight granted in the United States. While the company's primary focus remains achieving US regulatory approval, this European patent marks a significant step toward international commercialization.Stenoparib functions as an orally available, small-molecule inhibitor targeting both PARP1/2 and Tankyrase 1 and 2. The drug's unique therapeutic action, which combines PARP inhibition with Wnt pathway blocking, shows promise in cancer treatment, particularly for advanced ovarian cancer patients currently being evaluated in a phase 2 clinical trial (NCT03878849).

Allarity Therapeutics announced on October 22, 2024, that the European Patent Office (EPO) will grant a patent for its Drug Response Predictor (DRP) companion diagnostic specific to stenoparib, the company's dual-targeted PARP/Tankyrase inhibitor. This patent strengthens Allarity's market position for both stenoparib and its companion diagnostic technology, which identifies patients most likely to benefit from treatment.The company is pursuing patent applications for the Stenoparib DRP companion diagnostic in other major markets, including the United States, Japan, China, Australia, and India. Allarity has already secured 17 patents for drug-specific DRPs, with eight granted in the United States. While the company's primary focus remains achieving US regulatory approval, this European patent marks a significant step toward international commercialization.Stenoparib functions as an orally available, small-molecule inhibitor targeting both PARP1/2 and Tankyrase 1 and 2. The drug's unique therapeutic action, which combines PARP inhibition with Wnt pathway blocking, shows promise in cancer treatment, particularly for advanced ovarian cancer patients currently being evaluated in a phase 2 clinical trial (NCT03878849).